BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
Breast Cancer
,
Liver
,
Laryngoscope
,
Lovastatin
,
rs2476601
,
EGFR
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
indol
Summary
General Info
Curated Studies
Most Correlated Studies
L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (1 of 4)
L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (3 of 4)
L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (2 of 4)
L1000 CMAP - Hepatocellular carcinoma HEPG2 cells treated with small molecule perturbagens
L1000 CMAP - Breast adenocarcinoma SKBR3 cells treated with small molecule perturbagens
Explore Curated Studies Results
Literature
Most Relevant Literature
Base-mediated cascade synthesis of indole diolefins: a route to spiro[cyclopentene-indole]thiones an…
Electrochemical Dearomatization of Indoles: Access to Diversified Fluorine-Containing Spirocyclic In…
Cascade Nucleophilic Addition-Cyclic Michael Addition of Arynes and Indoles Bearing Michael Acceptor…
NiH-catalyzed dearomative hydroalkylation of indoles.
Phosphoric Acid Catalyzed Electrophilic Thiocyanation of Indoles: Access to SCN-Containing Aryl-Indo…
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
Midostaurin in Indolent Systemic Mastocytosis
Indolent Non Follicular Lymphomas Prognostic Project
Treatment of Indolent Systemic Mastocytosis With PA101
Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Ly…
Study With Rituximab-Gemcitabine/Oxaliplatin in Relapsed Indolent Lymphoma
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ